Mohawk Restasis deal could backfire on all pharma patent holders, not just Allergan

Mohawk Restasis deal could backfire on all pharma patent holders, not just Allergan

Last week saw a further backlash against Allergan’s 2017 Saint Regis Mohawk deal, with the introduction of proposed legislation to eliminate sovereign immunity as grounds for exemption from cancellation hearings before the US Patent and Trademark…

Unlock unlimited access to all IAM content